TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01712828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg Lenalidomide capsule will be administered orally once in the first period, and once with Quinidine in the second period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg Lenalidomide capsule will be administered orally once in the first period, and once with Quinidine in the second period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: 300 mg of Quinidine will be administered orally every 12 hours for 1 day followed by 600 mg of Quinidine administered orally every 12 hours for the next 4 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25 mg/mL injection of Temsirolimus will be given directly into the vein over 30 minutes once in the second period and once with Lenalidomide in the third period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Just before Temsirolimus is given, 25 mg of Diphenhydramine (Benadryl) will be given directly into the vein to decrease chances of an allergic reaction to Temsirolimus.
Study: NCT03627793

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistance training
Description: Moving muscles against loads with the purpose of increasing strength.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Moving muscles against loads with the purpose of increasing strength.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Moving muscles against loads with the purpose of increasing strength.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistance training
Description: Moving muscles against loads with the purpose of increasing strength.
Study: NCT00484471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: 15-30 mg/day aripiprazole, 22 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproate
Description: sufficient dose as determined by investigator to maintain the therapeutic level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: valproate
Description: sufficient dose as determined by investigator to maintain the therapeutic level.
Study: NCT04481568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PES-4-BPSD Model
Description: We will conduct a non-randomized preliminary efficacy trial, enrolling N=158 patients (79 control and 79 intervention). The primary outcome will be presence of BPSD as measured by a patient's total score on the Neuropsychiatric Inventory-Questionnaire (NPI-Q) during hospitalization. A multi-modal approach (including chart review and HCG questionnaires) will be used to determine the presence and severity of BPSD.
Study: NCT00484471

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to aripiprazole, 22 weeks
Study: NCT03776474

Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml

Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml

Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
Study: NCT04494269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50mg
Description: Oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50mg
Description: Oral administration once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegoprazan 50mg
Description: Oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50mg
Description: Oral administration once daily
Study: NCT03259152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone.
Study: NCT04481568

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The attention control condition
Description: On this unit, the management of patients who display BPSD is performed by nurse assistants, rather than PES. Therefore, in order to test the added layer of PES staff, the nurse assistants on the control unit will receive equivalent dementia care education and training as well as staff support (please refer to NCT# 04179721 for more details on this aim).
Study: NCT00917826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine Butyrate
Description: 1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: 5 mg/kg administered IV over 1 hour (Days 1-5 of each 21 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: 900 mg BID for 16 days (Days 6-21 of each 21 day cycle)
Study: NCT00798811

Intervention type: PROCEDURE
Group type: OTHER
Intervention: high-dose chemotherapy and autologous stem cell rescue
Description: Surgery -\> enroll Pre-RT chemotherapy (2 cycles: A1, B1) PBSC collection during first cycle (A1) (2nd look surgery if necessary) RT (Reduced dose CSI) Post-RT chemotherapy (4 cycles: A2, B2, A3, B3) (if relapse or progression prior to HDCT, off study -\> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: high-dose chemotherapy and autologous stem cell rescue
Description: Surgery pre-HDCT chemotherapy (6 cycles: A1, B1, A2, B2, A3, B3) PBSC collection during first cycle of chemotherapy (A1) (2nd look surgery if necessary) (if relapse or progression prior to HDCT, off study -\> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM) (RT if necessary) Observe
Study: NCT02398669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin hydrochloride
Description: A single 10 mg dose of oral tablet formulation of lorcaserin hydrochloride will be administered with 240 mL of water.
Study: NCT02655926

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Participants undergo implantation of bilateral electrodes at both the VS/VC and STN sites through a single burr hole under general anaesthesia. High-resolution MRI scans are used to calculate target coordinates and to verify accurate electrode location post-surgery. Each STN electrode have 4 electrical contacts at its distal tip (with a 0.5mm separation) and each VS/VC electrode have 4 electrical contacts at its distal tip (with a 1.5mm separation) to allow fine tuning of the exact site for stimulation delivery. Two non-rechargeable batteries (Activa PC) are connected to the electrodes and positioned under the skin of the right and left chest wall so that they correspond to the same set of electrodes for each patient: one for the 2 STN electrodes and one for the 2 VC/VS electrodes.
Study: NCT00798811

Intervention type: PROCEDURE
Group type: OTHER
Intervention: high-dose chemotherapy and autologous stem cell rescue
Description: (Surgery if possible) Chemotherapy (4 cycles) PBSC collection during first cycle of chemotherapy during 4th cycle of chemotherapy (if BM involvement) (RT, if possible, after PBSC collection) (if less than PR prior to HDCT, off study) HDCT1 (CTE) HDCT2 (CM)
Study: NCT03566277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Participants will have access to a wrist-worn activity monitor and have a daily step goal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Participants will have a deposit contract, wherein they will lose money if a goal is not reached, or double their money if a goal is reached

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Participants will receive text message feedback each day about progress towards their goal
Study: NCT00873730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Etanercept 50 mg twice a week (BIW) for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept/placebo
Description: Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks
Study: NCT03679559

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Continue usual physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention (home walking program and resistance training)
Description: Complete home-based walking program and resistance training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention (home-based Zumba program and resistance training)
Description: Complete home-based Zumba program and resistance training
Study: NCT02656719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous tracheostomy
Description: Ultrasound guided percutaneous tracheostomy
Study: NCT03679559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention (HIIT program and resistance training)
Description: Complete HIIT program and resistance training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention (HIIT program and resistance training)
Description: Complete HIIT program and resistance training
Study: NCT02656719

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy guided percutaneous tracheostomy
Description: Bronchoscopy guided percutaneous tracheostomy
Study: NCT04127097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cartoon group
Description: The children in the groups were distracted by watching cartoon 2 minutes before treatment, until the process was over
Study: NCT03452215

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mobile Phone Application Educational Resources
Description: Mobile Phone Application Educational Resources

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone Application Educational Resources
Description: Mobile Phone Application Educational Resources

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone Application GWG Tracker
Description: Mobile Phone Application GWG Tracker
Study: NCT03679559

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention (HIIT program and resistance training)
Description: Complete HIIT program and resistance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Watch video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Watch video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Watch video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Wear Fitbit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Wear Fitbit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Wear Fitbit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04533113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carious tissue selective removal
Description: Carious tissue selective removal in deep carious lesions in posterior teeth, using one of three materials as a liner under the final composite restoration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carious tissue selective removal
Description: Carious tissue selective removal in deep carious lesions in posterior teeth, using one of three materials as a liner under the final composite restoration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carious tissue selective removal
Description: Carious tissue selective removal in deep carious lesions in posterior teeth, using one of three materials as a liner under the final composite restoration
Study: NCT03513666

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug intervention
Description: anti-PD-1 monoclonal antibody Toripalimab injection combined with Pemetrexed and carboplatin
Study: NCT04110314

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Reminders for Influenza Vaccination: Gain-framed
Description: Patients receive gain-framed reminder/recall messages via the patient portal to get an influenza vaccination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Reminders for Influenza Vaccination: Gain-framed
Description: Patients receive gain-framed reminder/recall messages via the patient portal to get an influenza vaccination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Reminders for Influenza Vaccination: Loss-framed
Description: Patients receive loss-framed reminder/recall messages via the patient portal to get an influenza vaccination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Reminders for Influenza Vaccination: Loss-framed
Description: Patients receive loss-framed reminder/recall messages via the patient portal to get an influenza vaccination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-commitment prompt
Description: Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-commitment prompt
Description: Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-commitment prompt
Description: Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
Study: NCT01045005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration ofOxygen and carbon dioxide
Description: Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Oxygen and carbon dioxide
Description: Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
Study: NCT05687097

Intervention type: DEVICE
Intervention: Home-based sleep screening test or hospital-unattended sleep screening test
Description: ApneaLink device will be used to assess the number of apnea and hypopnea events per hour of sleep.

Intervention type: DEVICE
Intervention: Home-based sleep screening test or hospital-unattended sleep screening test
Description: ApneaLink device will be used to assess the number of apnea and hypopnea events per hour of sleep.

Intervention type: DEVICE
Intervention: Home-based sleep screening test or hospital-unattended sleep screening test
Description: ApneaLink device will be used to assess the number of apnea and hypopnea events per hour of sleep.

Intervention type: DEVICE
Intervention: Home-based sleep screening test or hospital-unattended sleep screening test
Description: ApneaLink device will be used to assess the number of apnea and hypopnea events per hour of sleep.

Intervention type: DEVICE
Intervention: Cardiovascular beat-to-beat monitoring
Description: CareTaker device will be used to continuously record the participant's arterial blood pressure and heart rate during sleep.

Intervention type: DEVICE
Intervention: Cardiovascular beat-to-beat monitoring
Description: CareTaker device will be used to continuously record the participant's arterial blood pressure and heart rate during sleep.

Intervention type: DEVICE
Intervention: Cardiovascular beat-to-beat monitoring
Description: CareTaker device will be used to continuously record the participant's arterial blood pressure and heart rate during sleep.

Intervention type: DEVICE
Intervention: Cardiovascular beat-to-beat monitoring
Description: CareTaker device will be used to continuously record the participant's arterial blood pressure and heart rate during sleep.

Intervention type: DEVICE
Intervention: ECG monitoring
Description: Faror Bithium 180 device will be used to continuously record the participant's ECG during sleep.

Intervention type: DEVICE
Intervention: ECG monitoring
Description: Faror Bithium 180 device will be used to continuously record the participant's ECG during sleep.

Intervention type: DEVICE
Intervention: ECG monitoring
Description: Faror Bithium 180 device will be used to continuously record the participant's ECG during sleep.
Study: NCT02944162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD33 CAR-NK cells
Description: The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD33 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD33.
Study: NCT03566004

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Stool specimen collection
Description: The stool specimen collection was performed at the hospital or at home using a disposable device to be placed on the toilet seat and an E-nat Tube sent by postal to the lab.
Study: NCT03822429

Intervention type: DRUG
Intervention: Controlled ovarian stimulation
Description: Hormonal therapy to induce ovulation by multiple ovarian follicles

Intervention type: DRUG
Intervention: Controlled ovarian stimulation
Description: Hormonal therapy to induce ovulation by multiple ovarian follicles

Intervention type: DRUG
Intervention: Controlled ovarian stimulation
Description: Hormonal therapy to induce ovulation by multiple ovarian follicles

Intervention type: DRUG
Intervention: Controlled ovarian stimulation
Description: Hormonal therapy to induce ovulation by multiple ovarian follicles
Study: NCT04630704

Intervention type: DEVICE
Intervention: Pedra
Description: Diffuse speckle contrast analysis perfusion system

Intervention type: DEVICE
Intervention: Pedra
Description: Diffuse speckle contrast analysis perfusion system

Intervention type: DEVICE
Intervention: Pedra
Description: Diffuse speckle contrast analysis perfusion system
Study: NCT05119842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APrevent® VOIS-Implant
Description: To compare the voice quality assessed by the change in G-Score from GRBAS-Scale between before and after permanent APrevent® VOIS implantation.
Study: NCT04957147

Intervention type: OTHER
Intervention: 12 months of guideline-directed heart failure therapy
Description: Standard guideline-directed heart failure drug +/- device therapy
Study: NCT03514277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 30 mL bupivacaine 0.5% w/v solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 30 mL bupivacaine 0.5% w/v solution
Study: NCT02965105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Catheter
Description: This is a newly developed intermittent catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Catheter
Description: This is a newly developed intermittent catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Speedicath
Description: This is a marketed Catheter which is used as comparator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Speedicath
Description: This is a marketed Catheter which is used as comparator
Study: NCT00414167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: 300 mg per day for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01538966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegvisomant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegvisomant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegvisomant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanreotide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanreotide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanreotide
Study: NCT05687097

Intervention type: DEVICE
Intervention: ECG monitoring
Description: Faror Bithium 180 device will be used to continuously record the participant's ECG during sleep.
Study: NCT04574453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iracross
Description: Administration of max 2ml of Iracross at first visit

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Iraline
Description: Administration of maximum 2 ml of Iraline at visit 1 to visit 3, 4 and 5 depending of suject's need
Study: NCT02735980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV